SCM
INM icon

Suvretta Capital Management’s InMed Pharmaceuticals INM Stock Holding History

Suvretta Capital Management’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$155K Buy
+100,000
New +$110K ﹤0.01% 96

Other funds holding INM

ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UFM
Ursa Fund Management Danville, California $1.28B AUM 89.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Suvretta Capital Management's INM Position: Q2 2026 in Review

Suvretta Capital Management opened a new position in InMed Pharmaceuticals (INM) in Q2 2026: 100,000 shares worth $155K. The stake represents ﹤0.01% of the portfolio and ranks #96 among its holdings.

20 funds tracked by Wall St. Rank hold INM as of Q2 2026.

  • Suvretta Capital Management held 100,000 shares of InMed Pharmaceuticals worth $155K as of Q2 2026.
  • InMed Pharmaceuticals was a new Suvretta Capital Management position in Q2 2026.
  • InMed Pharmaceuticals made up ﹤0.01% of Suvretta Capital Management's portfolio in Q2 2026, its #96 holding.
  • 20 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q2 2026.

Based on Suvretta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.